Organic Semiconductors: Commercialisation and the Technical Challenges Ahead

Dr. Giles Lloyd has worked in the field of organic electronics for 13 years including receiving a PhD from the University of Liverpool specializing in thin film transistor design and development using organic semiconductors. For the last 8 years he has worked on material and process development at Avecia and more recently, Merck following the acquisition of the Avecia group in March 2005. His role involved material development and device optimization leading on to customer project management where he now works closely with Merck's global customer base to optimize and improve Merck's material and formulation offerings in the Organic Electronics industry.

Merck is a global pharmaceutical and chemical enterprise. Its success is characterized by innovations from entrepreneurial employees. The pharmaceuticals business sector comprises innovative prescription drugs, e.g. for the treatment of cancer, neurodegenerative diseases and growth disorders, cardiovascular diseases and infertility. Added to this are consumer health care

products. The Chemicals business sector offers chemicals for sophisticated applications: liquid crystals for displays, effect pigments for industry and cosmetics, analytical reagents and test kits, as well as products and services along the entire process chain of the pharmaceutical and biotech industries.

Merck is the world's oldest pharmaceutical and chemical company - its roots date back to 1668. With more than 60 sites around the world, Merck is at home in nearly all industrial countries. The development and commercialisation of printable organic materials and formulations for emerging displays and electronics applications and markets is based at Merck's Advanced Technologies - Chilworth (AT-C) Technical Centre, Southampton, UK.